Covis announced the launch of two new dosage strengths for Lanoxin (digoxin): 0.0625mg and 0.1875mg strength tablets. Lanoxin tablets are already available in 0.25mg and 0.125mg dosage strengths.

RELATED: Cardiovascular Disorders Resource Center

Lanoxin is a cardiac glycoside approved for the treatment of mild-to-moderate heart failure (with a diuretic and an ACE inhibitor when possible), to increase myocardial contractility in pediatric patients with heart failure, and for the control of ventricular response rate in chronic atrial fibrillation.

Its actions are mediated through its effects on inhibiting Na+/K+ ATPase, an enzyme responsible for maintaining the intracellular milieu throughout the body. This results in an increase in the force and velocity of myocardial systolic contraction, a slowing of the heart rate, decreased conduction velocity through the AV node, and a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system.

All four strengths of Lanoxin tablets are available in 100- and 1000-count bottles.

For more information call (866) 488-4423 or visit